TREATMENT PATTERNS AMONG LOWER-INCOME INDIAN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER HARBORING EGFR MUTATIONS OR ALK REARRANGEMENTS

被引：2
|
作者：
Vashistha, Vishal
Garg, Avneet
Iyer, Hariharan
Jain, Deepali
Madan, Karan
Guleria, Randeep
Mohan, Anant
机构：
来源：
CHEST | 2020年 / 158卷 / 04期
关键词：
D O I：
10.1016/j.chest.2020.08.1621
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：1869A / 1869A
页数：1
相关论文
共 50 条
  • [21] Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations
    Wells, Leah
    Qin, Angel
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (12) : 1978 - 1993
  • [22] Impact of EGFR mutations on treatment of non-small cell lung cancer
    Bruce E. Johnson
    David Jackman
    Pasi A. Jänne
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 5 - 9
  • [23] Impact of EGFR mutations on treatment of non-small cell lung cancer
    Johnson, Bruce E.
    Jackman, David
    Janne, Pasi A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (Suppl 1) : S5 - S9
  • [24] What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements
    Cooper, Wendy A.
    O'Toole, Sandra
    Boyer, Michael
    Horvath, Lisa
    Mahar, Annabelle
    PATHOLOGY, 2011, 43 (02) : 103 - 115
  • [25] Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib
    Yiming Zhao
    Shuyuan Wang
    Bo Zhang
    Rong Qiao
    Jianlin Xu
    Lele Zhang
    Yanwei Zhang
    Baohui Han
    Targeted Oncology, 2019, 14 : 169 - 178
  • [26] Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib
    Zhao, Yiming
    Wang, Shuyuan
    Zhang, Bo
    Qiao, Rong
    Xu, Jianlin
    Zhang, Lele
    Zhang, Yanwei
    Han, Baohui
    TARGETED ONCOLOGY, 2019, 14 (02) : 169 - 178
  • [27] The Impact of Eligibility for Anti-Angiogenic Treatment to the Prognosis of Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations
    Kodama, H.
    Kenmotsu, H.
    Yabe, M.
    Nishioka, N.
    Miyawaki, E.
    Miyawaki, T.
    Mamesaya, N.
    Kobayashi, H.
    Omori, S.
    Wakuda, K.
    Ono, A.
    Naito, T.
    Murakami, H.
    Takahashi, T.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S618 - S618
  • [28] DETECTING EGFR MUTATIONS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Hammoudeh, Z. A.
    Antonova, O.
    Staneva, R.
    Nikolova, D.
    Kyuchukov, Y.
    Penev, A.
    Mintchev, T.
    Koleva, V
    Hadjidekova, S.
    Toncheva, D.
    BALKAN JOURNAL OF MEDICAL GENETICS, 2018, 21 (01) : 13 - 17
  • [29] Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations
    Ichihara, Eiki
    Hotta, Katsuyuki
    Takigawa, Nagio
    Kudo, Kenichiro
    Kato, Yuka
    Hondaa, Yoshihiro
    Hayakawa, Hiromi
    Minami, Daisuke
    Sato, Akiko
    Tabata, Masahiro
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    LUNG CANCER, 2013, 81 (03) : 435 - 439
  • [30] Outcomes of EGFR-TKIs for patients with non-small cell lung cancer harboring EGFR mutations with poor performance status
    Hashimoto, K.
    Okuma, Y.
    Hakozaki, T.
    Watanabe, K.
    Hosomi, Y.
    ANNALS OF ONCOLOGY, 2018, 29
12345